
    
      This study proposes to document the presence of clonal emergence and regression during
      radium-223 therapy for metastatic prostate cancer by serial ctDNA analysis of
      tumor-associated mutations, using the clinically-available Guardant 360 platform. These data
      may provide important mechanistic insights into radium-223 therapy by 1) identifying
      mutations associated with radium-223 resistance or sensitivity, 2) providing new markers of
      treatment response in an individual, and 3) revealing antitumor effects from radium-223 that
      are not easily recognized with standard tumor response metrics. Positive finding based on
      this clinically-available platform will be readily applied by the oncology treatment
      community.
    
  